<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, the need for a safe and effective vaccine against coronaviruses is generally appreciated. Numerous human vaccine trials for are under way targeting SARS CoV‐2. Historically, support for vaccine development after the SARS epidemic was short‐lived. Vaccine development for SARS included a phase 1 clinical trial of a SARS‐CoV‐1 vaccine which showed that the vaccine was safe, and effectively stimulated the production of neutralizing antibodies.
 <xref rid="hed26275-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref> Unfortunately, when the SARS epidemic ended, vaccine development was abandoned.
 <xref rid="hed26275-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> The impact of the COVID‐19 epidemic suggests that interest in the development of a vaccine will be more enduring.
</p>
